Abstract:Kai-Michael Beeh, 1 Karl Scheithe, 2 Heike Schmutzler, 3 Saskia Krüger 3 1 Insaf Respiratory Research Institute, Wiesbaden, Germany; 2 Department of Biostatistics, GKM Gesellschaft Für Therapieforschung mbH, Munich, Germany; 3 Medical Department, BERLIN-CHEMIE AG, Berlin, Germany Correspondence: Kai-Michael Beeh, Insaf Respiratory Research Institute, Biebricher Allee 34, Wiesbaden, 65187, Germany, Tel +49 (0) 611 9854410, Email Purpose: Real-life effectiveness data on once-daily single-inhaler triple therapy (odSITT) with the inhaled corticosteroid fluticasone furoate (FF), the long-acting muscarinic antagonist umeclidinium (UMEC), and the long-acting β 2 -agonist vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) are important to complement evidence from well-controlled randomized clinical trials. Effectiveness of odSITT was quantified by assessing health status and symptoms in usual care. Patients and Methods: ELLITHE was a single-country (Germany), multicenter, open-label, non-interventional effectiveness study between 2020 and 2022, evaluating the effect of treatment initiation with FF/UMEC/VI 100/62.5/25 μg once-daily via the ELLIPTA inhaler on improvements in clinical outcomes versus baseline in COPD patients. The primary endpoint was the change in the total COPD Assessment Test (CAT) score between baseline and month 12. Key secondary endpoints included change in CAT score over time, occurrence of exacerbations until month 12, changes in forced expiratory volume in one second (FEV 1 ), inhaler adherence, and safety. Results: Nine hundred and six patients were included (age 66.6 years, 55.6% male, mean FEV 1 52.6% of predicted, mean CAT 21.5 units, 1.4 exacerbations/year pre-study). About 63.9% of patients were escalated from dual therapies, and 18% were switched from multiple-inhaler triple therapies. Reductions in CAT score at month 12 were statistically significant and above the threshold of clinical importance (− 2.6 units; p < 0.0001). CAT score also improved at interim visits. CAT improvements were more pronounced in patients with high baseline scores and better inhaler adherence. Exacerbations during follow-up were rare (0.2 events/year) compared to pre-study (1.4 events/year). FEV 1 was improved by 93 mL (p < 0.0001). No new safety effects were observed. Conclusion: In usual care, treatment with odSITT resulted in significant and clinically relevant improvements of CAT score and FEV 1 in COPD patients, regardless of the occurrence of exacerbations. These findings challenge the current guideline recommendations for SITT only in patients experiencing exacerbations. Keywords: CAT score, real-world evidence, lung function, exacerbation, treatment adherence Triple therapy with inhaled corticosteroid (ICS), long-acting β 2 -agonist (LABA) and long-acting muscarinic antagonist (LAMA) is currently approved as treatment option for moderate-to-severe chronic obstructive pulmonary disease (COPD) patients uncontrolled on dual-combination therapies. 1–3 As of today, three single-inhaler triple therapies (SITT) have been licensed for COPD treatment, avoiding the necessity to use multiple inhalers and more frequent dosing schemes, thus offering the potential to improve treatment adherence, which could in turn lead to improved clinical outcomes. 4,5 Current national 6 and international 7 guidelines and strategies recommend triple therapy for patients experiencing frequent moderate or severe exacerbations as an escalation step from long-acting bronchodilator therapy. The use of blood eosinophil count is also strongly promoted to identify patients with high likelihood of benefitting from an ICS-containing therapy. 8 In contrast, triple therapy is not mentioned as a part of follow-up therapy in non-exacerbating patients with persistent symptoms, namely dyspnea, beyond dual LAMA/LABA bronchodilation. This recommendation is somehow more restrictive than the current approval status of SITTs, which includes COPD patients uncontrolled on either dual therapies, regardless of whether this is defined by persistent symptoms and/or exacerbations. In several large-scale, randomized controlled trials (RCTs), once-daily SITT (odSITT) with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) has demonstrated a wide range of clinical benefits, including reduction of moderate-to-severe exacerbations and symptoms while improving health status and lung function versus dual therapies FF/VI, UMEC/VI 9 and budesonide/formoterol. 10 Importantly, a relative reduction in the mortality rate was observed versus dual LAMA/L -Abstract Truncated-

Effects of one year treatment with extrafine fixed triple inhaled therapy in moderate COPD in a real-life setting - results of the RATIONALE study

Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study

The Real-World Efficacy of Fixed Triple Inhalation Therapy in the Treatment of Moderate COPD Patients (RATIONALE Study)

Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

"Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study"

Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA

Characteristics of COPD patients treated with single‑inhaler triple therapy in real-life clinical practice

Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain

Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)

Triple Therapy in COPD in Real Life: Is It Better to Use Single or Multiple Inhalers?

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)

Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD

Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting

TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life

Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study

Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study)

Efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI in the treatment of stable COPD